Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Walleye Capital LLC

Walleye Capital LLC cut its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 75.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,073 shares of the biopharmaceutical company’s stock after selling 172,400 shares during the quarter. Walleye Capital LLC owned about 0.09% of Sage Therapeutics worth $304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Picton Mahoney Asset Management raised its holdings in shares of Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Sage Therapeutics in the 4th quarter valued at approximately $49,000. Ieq Capital LLC acquired a new stake in Sage Therapeutics in the 4th quarter valued at approximately $57,000. US Bancorp DE raised its stake in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 2,268 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 2,446 shares during the period. 99.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SAGE. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Canaccord Genuity Group dropped their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, February 12th. Wedbush reiterated a “neutral” rating and issued a $6.00 price objective on shares of Sage Therapeutics in a report on Wednesday, February 12th. HC Wainwright reissued a “neutral” rating and set a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Scotiabank decreased their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research note on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.81.

Sage Therapeutics Stock Performance

Sage Therapeutics stock opened at $7.79 on Friday. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $14.97. The firm has a market capitalization of $478.94 million, a price-to-earnings ratio of -1.18 and a beta of 0.48. The company has a 50 day moving average price of $7.51 and a 200 day moving average price of $6.74.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Equities analysts forecast that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.